MicroRNA 1248 (miR-1248)

MicroRNA 1248 (miR-1248) is a small non-coding RNA of approximately 20–24 nucleotides that functions in the post-transcriptional regulation of gene expression in multicellular organisms by modulating mRNA stability and translation[3]. It acts both canonically (by binding to mRNAs and promoting degradation or inhibiting translation) and non-canonically (for instance, directly activating signaling proteins)[1][3]. miR-1248 has been shown to upregulate or downregulate diverse transcripts, including pivotal roles in interferon signaling (by binding the DDX58/RIG-I and promoting IFN-β production), modulation of calcium channel signaling (by targeting ITPR3), and direct or indirect regulation of inflammatory cytokines (IL-5, IL-6, IL-8)[1][5][7]. High miR-1248 expression is associated with progression of certain cancers, notably pediatric low-grade glioma, acting oncogenically by suppressing key tumor suppressor genes such as CDKN1A (p21), FRK, SPOP, VHL, and MTAP[2]. In autoimmune disease, such as Sjögren’s syndrome, miR-1248 contributes to gland dysfunction by disrupting IFN and calcium signaling[1]. It is also implicated as a potential serum biomarker of aging and in asthma pathogenesis[1][5][7]. No direct small-molecule or biologic drugs target miR-1248 in current therapeutic use, but its status as an oncogenic and immunomodulatory microRNA makes it a potential future therapeutic target or biomarker[2].

Other names

MIR1248hsa-mir-1248MIRN1248mir-1248